The Belfast-based app developer has closed a pre-seed round to scale its team and enter the US market.
"The reality is the big tech companies have monetised our time and attention. Every second spent on their platforms translates to revenue. The incentivisation model is all wrong, which is why we as a society are realising a broad range of negative outcomes, from diminishing attention spans to rising anxiety and body image issues. Our mission is to restore individual agency, empowering people to lead healthy, intentional and fulfilling lives."
The pre-seed round was led by Two Magnolias to support the sports technology startup as it launches across Europe.
"We are absolutely thrilled to be leading this round for Movetru. Naomi and her team are solving a critical gap in sports performance with grit, vision, and world-class execution. Movetru represents the best of Northern Ireland’s tech talent, and we are excited to back them on this journey."
The investment was backed by the GMC Life Sciences Fund By Praetura and NPIF II, Praetura Equity Finance.
"We’re building a future where everyone has the tools and confidence to take control of their health — wherever they are. This funding allows us to scale our digital platform, extend our reach into new communities, and strengthen our collaborations and integrations across employer, public health and primary care. Prevention has to be proactive, accessible and data-informed — and that’s exactly what SiSU Health delivers."
The London startup has raised £60k from Bethnal Green Ventures to develop its AI capabilities and expand corporate partnerships.
"This funding is a transformative moment for Legacy Compass. End-of-life planning is often met with avoidance, but it should be an opportunity to reflect, connect, and prepare with clarity. With Bethnal Green Ventures’ support, we are one step closer to making this process accessible, empowering, and human-centered for individuals and families worldwide."
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
